Аденокарцинома поджелудочной железы. Литература | ПРЕЦИЗИОННАЯ ОНКОЛОГИЯ

Аденокарцинома поджелудочной железы. Литература

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians 2014;64:9-29.
  2. McClusky DA, 3rd, Skandalakis LJ, Colborn GL, Skandalakis JE. Harbinger or hermit? Pancreatic anatomy and surgery through the ages—part 3. World journal of surgery 2002;26:1512-24.
  3. Moynihan B. Neoplasms of the pancreas. In: Moynihan B, ed. Abdominal Operations. Philadelphia: WB Saunders; 1906.
  4. Buchler MW, Wagner M, Schmied BM, Uhl W, Friess H, Z’Graggen K. Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Archives of surgery (Chicago, Ill : 1960) 2003;138:1310-4; discussion 5.
  5. Crile G, Jr. The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma. Surgery, gynecology & obstetrics 1970;130:1049-53.
  6. Muniraj T, Jamidar PA, Aslanian HR. Pancreatic cancer: a comprehensive review and update. Disease-a-month : DM 2013;59:368-402.
  7. Howlader N NA, Kraphco M, et al. SEER Cancer Statistics Review, 1975-2008. In: Institute NC, ed. Bethesda, MD2011.
  8. Anderson KE PJ, Mack TM. In: Schottenfeld D FJ, ed. Cancer Epidemiology and Prevention. New York: Oxford University Press; 1996:725-71.
  9. Brand RE, Lerch MM, Rubinstein WS, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007;56:1460-9.
  10. Ghadirian P, Boyle P, Simard A, Baillargeon J, Maisonneuve P, Perret C. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. International journal of pancreatology : official journal of the International Association of Pancreatology 1991;10:183-96.
  11. Silverman DT. Risk factors for pancreatic cancer: a case-control study based on direct interviews. Teratogenesis, carcinogenesis, and mutagenesis 2001;21:7-25.
  12. Barton JG, Schnelldorfer T, Lohse CM, et al. Patterns of pancreatic resection differ between patients with familial and sporadic pancreatic cancer. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2011;15:836-42.
  13. Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update on familial pancreatic cancer. Advances in surgery 2010;44:293-311.
  14. Amin S, McBride RB, Kline JK, et al. Incidence of subsequent pancreatic adenocarcinoma in patients with a history of nonpancreatic primary cancers. Cancer 2012;118:1244-51.
  15. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (New York, NY) 2009;324:217.
  16. Bartsch DK. Familial pancreatic cancer. The British journal of surgery 2003;90:386-7.
  17. Bartsch DK, Gress TM, Langer P. Familial pancreatic cancer—current knowledge. Nature reviews Gastroenterology & hepatology 2012;9:445-53.
  18. Fuchs CS, Colditz GA, Stampfer MJ, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Archives of internal medicine 1996;156:2255-60.
  19. Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surgical oncology clinics of North America 1998;7:67-91.
  20. Lowenfels AB MP, Whitcomb DC. Risk factors for cancer in hereditary pancreatitis. In: Whitcomb DC CJ, Ulrich CD, ed. The Medical Clinics of North America: Inherited Diseases of the Pancreas. Philadelphia: W.B. Saunders Co; 2000:3565-73.
  21. Hassan MM, Bondy ML, Wolff RA, et al. Risk factors for pancreatic cancer: case-control study. The American journal of gastroenterology 2007;102:2696-707.
  22. Hermann PC, Sancho P, Canamero M, et al. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. Gastroenterology 2014;147:1119-33.e4.
  23. Arslan AA, Helzlsouer KJ, Kooperberg C, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Archives of internal medicine 2010;170:791-802.
  24. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA : the journal of the American Medical Association 2001;286:921-9.
  25. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. British journal of cancer 2005;92:2076-83.
  26. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA : the journal of the American Medical Association 1995;273:1605-9.
  27. Muntoni S, Muntoni S, Draznin B. Effects of chronic hyperinsulinemia in insulin-resistant patients. Current diabetes reports 2008;8:233-8.
  28. Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA : the journal of the American Medical Association 2005;294:2872-8.
  29. Tsirambidis JV, Conwell DL, Zuccaro G. Chronic pancreatitis. MedGenMed : Medscape general medicine 2003;5:17.
  30. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. The New England journal of medicine 1993;328:1433-7.
  31. Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, et al. Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. Journal of the National Cancer Institute 2001;93:937-41.
  32. Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW, 3rd, Lowenfels AB. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. Journal of the National Cancer Institute 2003;95:381-7.
  33. Han X, Li J, Brasky TM, et al. Antioxidant intake and pancreatic cancer risk: the Vitamins and Lifestyle (VITAL) Study. Cancer 2013;119:1314-20.
  34. Larsson SC, Giovannucci E, Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 2006;131:1271-83.
  35. Bosetti C, Lucenteforte E, Bracci PM, et al. Ulcer, gastric surgery and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24:2903-10.
  36. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nature reviews Cancer 2002;2:897-909.
  37. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer cell 2003;4:437-50.
  38. Rooman I, Real FX. Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development? Gut 2012;61:449-58.
  39. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6:2969-72.
  40. van Heek NT, Meeker AK, Kern SE, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. The American journal of pathology 2002;161:1541-7.
  41. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, NY) 2008;321:1801-6.
  42. Brand R. Pancreatic cancer. Disease-a-month : DM 2004;50:545-55.
  43. Hidalgo M. Pancreatic cancer. The New England journal of medicine 2010;362:1605-17.
  44. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-7.
  45. Buchler P, Gazdhar A, Schubert M, et al. The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Annals of surgery 2005;242:791-800, discussion -1.
  46. Handra-Luca A, Hammel P, Sauvanet A, Lesty C, Ruszniewski P, Couvelard A. EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins. Journal of clinical pathology 2014;67:295-300.
  47. Buchler P, Reber HA, Buchler MW, Friess H, Hines OJ. VEGF-RII influences the prognosis of pancreatic cancer. Annals of surgery 2002;236:738-49; discussion 49.
  48. Hidalgo M, Maitra A. The hedgehog pathway and pancreatic cancer. The New England journal of medicine 2009;361:2094-6.
  49. Aghdassi A, Sendler M, Guenther A, et al. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 2012;61:439-48.
  50. Akita H, Nagano H, Takeda Y, et al. Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Oncogene 2011;30:3468-76.
  51. Theoharides TC. Mast cells and pancreatic cancer. The New England journal of medicine 2008;358:1860-1.
  52. Hermanek P. Pathology and biology of pancreatic ductal adenocarcinoma. Langenbeck’s archives of surgery / Deutsche Gesellschaft fur Chirurgie 1998;383:116-20.
  53. Nagakawa T, Kobayashi H, Ueno K, et al. The pattern of lymph node involvement in carcinoma of the head of the pancreas. A histologic study of the surgical findings in patients undergoing extensive nodal dissections. International journal of pancreatology : official journal of the International Association of Pancreatology 1993;13:15-22.
  54. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008;134:95-101.
  55. Chen N, Unnikrishnan IR, Anjana RM, Mohan V, Pitchumoni CS. The complex exocrine-endocrine relationship and secondary diabetes in exocrine pancreatic disorders. Journal of clinical gastroenterology 2011;45:850-61.
  56. Aggarwal G, Ramachandran V, Javeed N, et al. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice. Gastroenterology 2012;143:15107.e1.
  57. Abel EV, Simeone DM. Biology and clinical applications of pancreatic cancer stem cells. Gastroenterology 2013;144:1241-8.
  58. Adikrisna R, Tanaka S, Muramatsu S, et al. Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. Gastroenterology 2012;143:234-45.e7.
  59. Alhamdani MS, Youns M, Buchholz M, et al. Immunoassay-based proteome profiling of 24 pancreatic cancer cell lines. Journal of proteomics 2012;75:3747-59.
  60. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27:1806-13.
  61. Albers GH, Fleuren G, Escribano MJ, Nap M. Immunohistochemistry of CEA in the human pancreas during development, in the adult, chronic pancreatitis, and pancreatic adenocarcinoma. American journal of clinical pathology 1988;90:17-22.
  62. Aguilar S, Corominas JM, Malats N, et al. Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression. The American journal of pathology 2004;165:1129-39.
  63. Shi C, Merchant N, Newsome G, Goldenberg DM, Gold DV. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. Archives of pathology & laboratory medicine 2014;138:220-8.
  64. Dudeja V, Allen PJ. Premalignant cystic neoplasms of the pancreas. Seminars in oncology 2015;42:70-85.
  65. Adsay NV, Conlon KC, Zee SY, Brennan MF, Klimstra DS. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer 2002;94:62-77.
  66. Balsarkar D, Takahata S, Tanaka M. Intraductal papillary mucinous neoplasms of the pancreas: is the puzzle solved? Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 2013;32:213-21.
  67. Choi MG, Kim SW, Han SS, Jang JY, Park YH. High incidence of extrapancreatic neoplasms in patients with intraductal papillary mucinous neoplasms. Archives of surgery (Chicago, Ill : 1960) 2006;141:51-6; discussion 6.
  68. Eguchi H, Ishikawa O, Ohigashi H, et al. Patients with pancreatic intraductal papillary mucinous neoplasms are at high risk of colorectal cancer development. Surgery 2006;139:749-54.
  69. Marchegiani G, Malleo G, D’Haese JG, et al. Association between pancreatic intraductal papillary mucinous neoplasms and extrapancreatic malignancies. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2015;13:1162-9.
  70. Adsay NV. The «new kid on the block»: Intraductal papillary mucinous neoplasms of the pancreas: current concepts and controversies. Surgery 2003;133:459-63.
  71. Doi R, Fujimoto K, Wada M, Imamura M. Surgical management of intraductal papillary mucinous tumor of the pancreas. Surgery 2002;132:80-5.
  72. Terris B, Ponsot P, Paye F, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. The American journal of surgical pathology 2000;24:1372-7.
  73. Matsumoto T, Aramaki M, Yada K, et al. Optimal management of the branch duct type intraductal papillary mucinous neoplasms of the pancreas. Journal of clinical gastroenterology 2003;36:261-5.
  74. Rodriguez JR, Salvia R, Crippa S, et al. Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology 2007;133:72-9; quiz 309-10.
  75. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology : official journal of the International Association of Pancreatology (IAP) [et al] 2006;6:1732.
  76. Werner J, Fritz S, Buchler MW. Intraductal papillary mucinous neoplasms of the pancreas—a surgical disease. Nature reviews Gastroenterology & hepatology 2012;9:253-9.
  77. Fritz S, Klauss M, Bergmann F, et al. Small (Sendai negative) branch-duct IPMNs: not harmless. Annals of surgery 2012;256:313-20.
  78. Lee CJ, Scheiman J, Anderson MA, et al. Risk of malignancy in resected cystic tumors of the pancreas < or =3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional report. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2008;12:234-42.
  79. Nagai K, Doi R, Ito T, et al. Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. Journal of hepato-biliary-pancreatic surgery 2009;16:353-8.
  80. Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology : official journal of the International Association of Pancreatology (IAP) [et al] 2012;12:183-97.
  81. Sugiyama M, Izumisato Y, Abe N, Masaki T, Mori T, Atomi Y. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. The British journal of surgery 2003;90:1244-9.
  82. Furukawa T, Takahashi T, Kobari M, Matsuno S. The mucus-hypersecreting tumor of the pancreas. Development and extension visualized by three-dimensional computerized mapping. Cancer 1992;70:1505-13.
  83. Serikawa M, Sasaki T, Fujimoto Y, Kuwahara K, Chayama K. Management of intraductal papillarymucinous neoplasm of the pancreas: treatment strategy based on morphologic classification. Journal of clinical gastroenterology 2006;40:856-62.
  84. Levy P, Jouannaud V, O’Toole D, et al. Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006;4:460-8.
  85. Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 2002;123:1500-7.
  86. Hara T, Ikebe D, Odaka A, et al. Preoperative histological subtype classification of intraductal papillary mucinous neoplasms (IPMN) by pancreatic juice cytology with MUC stain. Annals of surgery 2013;257:1103-11.
  87. Alexander BM, Fernandez-Del Castillo C, Ryan DP, et al. Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy. Gastrointestinal cancer research : GCR 2011;4:116-21.
  88. Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. The American journal of pathology 2000;157:755-61.
  89. Grutzmann R, Post S, Saeger HD, Niedergethmann M. Intraductal papillary mucinous neoplasia (IPMN) of the pancreas: its diagnosis, treatment, and prognosis. Deutsches Arzteblatt international 2011;108:788-94.
  90. Traverso LW, Moriya T, Hashimoto Y. Intraductal papillary mucinous neoplasms of the pancreas: making a disposition using the natural history. Current gastroenterology reports 2012;14:106-11.
  91. Kang MJ, Jang JY, Lee KB, Chang YR, Kwon W, Kim SW. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Annals of surgery 2014;260:356-63.
  92. He J, Cameron JL, Ahuja N, et al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? Journal of the American College of Surgeons 2013;216:657-65; discussion 65-7.
  93. Hong SM, Park JY, Hruban RH, Goggins M. Molecular signatures of pancreatic cancer. Archives of pathology & laboratory medicine 2011;135:716-27.
  94. Kim TS, Fernandez-Del Castillo C. Diagnosis and Management of Pancreatic Cystic Neoplasms. Hematology/oncology clinics of North America 2015;29:655-74.
  95. Hart PA, Chari ST. Management of pancreatic mucinous cystic neoplasms: surgery or surveillance? Pancreatology : official journal of the International Association of Pancreatology (IAP) [et al] 2015;15:97-8.
  96. Robinson SM, Scott J, Oppong KW, White SA. What to do for the incidental pancreatic cystic lesion? Surgical oncology 2014;23:117-25.
  97. Crippa S, Salvia R, Warshaw AL, et al. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Annals of surgery 2008;247:571-9.
  98. Yamao K, Yanagisawa A, Takahashi K, et al. Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma: a multi-institutional study of the Japan pancreas society. Pancreas 2011;40:67-71.
  99. Haugk B. Pancreatic intraepithelial neoplasia-can we detect early pancreatic cancer? Histopathology 2010;57:503-14.
  100. Corbo V, Tortora G, Scarpa A. Molecular pathology of pancreatic cancer: from bench-to-bedside translation. Current drug targets 2012;13:744-52.
  101. Hristov AC, Cope L, Di Cello F, et al. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010;23:98-104.
  102. Bailey JM, Alsina J, Rasheed ZA, et al. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology 2014;146:245-56.
  103. Iacobuzio-Donahue CA. Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut 2012;61:1085-94.
  104. Fendrich V, Chen NM, Neef M, et al. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 2010;59:630-7.
  105. Matthaei H, Hong SM, Mayo SC, et al. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Annals of surgical oncology 2011;18:3493-9.
  106. Watanabe I, Sasaki S, Konishi M, et al. Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas 2004;28:160-5.
  107. Takhar AS, Palaniappan P, Dhingsa R, Lobo DN. Recent developments in diagnosis of pancreatic cancer. BMJ (Clinical research ed) 2004;329:668-73.
  108. Porta M, Fabregat X, Malats N, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2005;7:189-97.
  109. Bussom S, Saif MW. Methods and rationale for the early detection of pancreatic cancer. Highlights from the «2010 ASCO Gastrointestinal Cancers Symposium». Orlando, FL, USA. January 22-24, 2010. JOP : Journal of the pancreas 2010;11:128-30.
  110. Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology 2010;139:1076-80, 80.e1-2.
  111. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial PeutzJeghers syndrome. Gastroenterology 2000;119:1447-53.
  112. Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013;62:339-47.
  113. Harinck F, Konings IC, Kluijt I, et al. A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut 2015.
  114. Goggins M. Molecular markers of early pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23:4524-31.
  115. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989;110:704-9.
  116. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. The American journal of gastroenterology 1990;85:350-5.
  117. Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Annals of surgical oncology 2013;20:2188-96.
  118. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. Journal of gastrointestinal oncology 2012;3:105-19.
  119. Hata S, Sakamoto Y, Yamamoto Y, et al. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Annals of surgical oncology 2012;19:636-41.
  120. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. British journal of cancer 2005;93:7403.
  121. Sperti C, Pasquali C, Catalini S, et al. CA 19-9 as a prognostic index after resection for pancreatic cancer. Journal of surgical oncology 1993;52:137-41.
  122. Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian journal of surgical oncology 2011;2:88-100.
  123. Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015;523:177-82.
  124. Shrikhande SV, Barreto SG, Goel M, Arya S. Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature. HPB : the official journal of the International Hepato Pancreato Biliary Association 2012;14:658-68.
  125. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Annals of surgical oncology 2009;16:1727-33.
  126. Bronstein YL, Loyer EM, Kaur H, et al. Detection of small pancreatic tumors with multiphasic helical CT. AJR American journal of roentgenology 2004;182:619-23.
  127. Boujaoude J. Role of endoscopic ultrasound in diagnosis and therapy of pancreatic adenocarcinoma. World journal of gastroenterology : WJG 2007;13:3662-6.
  128. Eloubeidi MA, Tamhane A, Varadarajulu S, Wilcox CM. Frequency of major complications after EUS-guided FNA of solid pancreatic masses: a prospective evaluation. Gastrointestinal endoscopy 2006;63:622-9.
  129. Hewitt MJ, McPhail MJ, Possamai L, Dhar A, Vlavianos P, Monahan KJ. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointestinal endoscopy 2012;75:319-31.
  130. Rodriguez S, Faigel D. Absence of a dilated duct predicts benign disease in suspected pancreas cancer: a simple clinical rule. Digestive diseases and sciences 2010;55:1161-6.
  131. Edge S. AJCC cancer staging manual. 7th Edition ed. New York, NY: Springer; 2010.
  132. Rochefort MM, Ankeny JS, Kadera BE, et al. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Annals of surgical oncology 2013;20:4322-9.
  133. Pancreatic Adenocarcinoma: NCCN Clinical Practice Guidelines in Oncology Version 2.2015. 2015. (Accessed August 31, 2015, at http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.)
  134. Katz MH, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Annals of surgical oncology 2013;20:278795.
  135. Schima W, Fugger R, Schober E, et al. Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT. AJR American journal of roentgenology 2002;179:717-24.
  136. Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology 2014;146:291-304.e1.
  137. Ellsmere J, Mortele K, Sahani D, et al. Does multidetector-row CT eliminate the role of diagnostic laparoscopy in assessing the resectability of pancreatic head adenocarcinoma? Surgical endoscopy 2005;19:369-73.
  138. House MG, Yeo CJ, Cameron JL, et al. Predicting resectability of periampullary cancer with threedimensional computed tomography. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2004;8:280-8.
  139. Roche CJ, Hughes ML, Garvey CJ, et al. CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas. AJR American journal of roentgenology 2003;180:475-80.
  140. Tamm EP, Loyer EM, Faria S, et al. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdominal imaging 2006;31:568-74.
  141. Holzapfel K, Reiser-Erkan C, Fingerle AA, et al. Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer. Abdominal imaging 2011;36:179-84.
  142. Heinrich S, Goerres GW, Schafer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Annals of surgery 2005;242:235-43.
  143. Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. Journal of clinical gastroenterology 2006;40:923-9.
  144. Pappas SG, Christians KK, Tolat PP, et al. Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility? HPB : the official journal of the International Hepato Pancreato Biliary Association 2014;16:70-4.
  145. Bernheim BM. IV. Organoscopy: Cystoscopy of the Abdominal Cavity. Annals of surgery 1911;53:764-7.
  146. Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG. Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era? Journal of the American College of Surgeons 2009;208:87-95.
  147. Jimenez RE, Warshaw AL, Rattner DW, Willett CG, McGrath D, Fernandez-del Castillo C. Impact of laparoscopic staging in the treatment of pancreatic cancer. Archives of surgery (Chicago, Ill : 1960) 2000;135:409-14; discussion 14-5.
  148. Ahmed SI, Bochkarev V, Oleynikov D, Sasson AR. Patients with pancreatic adenocarcinoma benefit from staging laparoscopy. Journal of laparoendoscopic & advanced surgical techniques Part A 2006;16:458-63.
  149. Warshaw AL, Tepper JE, Shipley WU. Laparoscopy in the staging and planning of therapy for pancreatic cancer. American journal of surgery 1986;151:76-80.
  150. Schnelldorfer T, Gagnon AI, Birkett RT, Reynolds G, Murphy KM, Jenkins RL. Staging laparoscopy in pancreatic cancer: a potential role for advanced laparoscopic techniques. Journal of the American College of Surgeons 2014;218:1201-6.
  151. Contreras CM, Stanelle EJ, Mansour J, et al. Staging laparoscopy enhances the detection of occult metastases in patients with pancreatic adenocarcinoma. Journal of surgical oncology 2009;100:663-9.
  152. Allen VB, Gurusamy KS, Takwoingi Y, Kalia A, Davidson BR. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. The Cochrane database of systematic reviews 2013;11:Cd009323.
  153. Tapper E, Kalb B, Martin DR, Kooby D, Adsay NV, Sarmiento JM. Staging laparoscopy for proximal pancreatic cancer in a magnetic resonance imaging-driven practice: what’s it worth? HPB : the official journal of the International Hepato Pancreato Biliary Association 2011;13:732-7.
  154. Velanovich V. The effects of staging laparoscopy on trocar site and peritoneal recurrence of pancreatic cancer. Surgical endoscopy 2004;18:310-3.
  155. Yoshioka R, Saiura A, Koga R, et al. The implications of positive peritoneal lavage cytology in potentially resectable pancreatic cancer. World journal of surgery 2012;36:2187-91.
  156. Meszoely IM, Lee JS, Watson JC, Meyers M, Wang H, Hoffman JP. Peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreas. The American surgeon 2004;70:208-13; discussion 13-4.
  157. Camacho D, Reichenbach D, Duerr GD, Venema TL, Sweeney JF, Fisher WE. Value of laparoscopy in the staging of pancreatic cancer. JOP : Journal of the pancreas 2005;6:552-61.
  158. Pisters PW, Lee JE, Vauthey JN, Charnsangavej C, Evans DB. Laparoscopy in the staging of pancreatic cancer. The British journal of surgery 2001;88:325-37.
  159. Karachristos A, Scarmeas N, Hoffman JP. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2005;9:1286-92.
  160. Lewis JJ, Kowalski TE. Endoscopic ultrasound and fine needle aspiration in pancreatic cancer. Cancer journal (Sudbury, Mass) 2012;18:523-9.
  161. Nawaz H, Fan CY, Kloke J, et al. Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis. JOP : Journal of the pancreas 2013;14:484-97.
  162. Krishna NB, Mehra M, Reddy AV, Agarwal B. EUS/EUS-FNA for suspected pancreatic cancer: influence of chronic pancreatitis and clinical presentation with or without obstructive jaundice on performance characteristics. Gastrointestinal endoscopy 2009;70:70-9.
  163. Katz MH, Fleming JB, Lee JE, Pisters PW. Current status of adjuvant therapy for pancreatic cancer. The oncologist 2010;15:1205-13.
  164. Parmar AD, Vargas GM, Tamirisa NP, Sheffield KM, Riall TS. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. Surgery 2014;156:280-9.
  165. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies. Cell 2012;148:362-75.
  166. Palmer DH, Stocken DD, Hewitt H, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Annals of surgical oncology 2007;14:2088-96.
  167. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS medicine 2010;7:e1000267.
  168. Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Annals of surgery 2015;261:12-7.
  169. Sherman WH, Chu K, Chabot J, et al. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma. Cancer 2015;121:673-80.
  170. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26:3487-95.
  171. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26:3496-502.
  172. Tzeng CW, Tran Cao HS, Lee JE, et al. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2014;18:16-24; discussion -5.
  173. Tempero MA, Malafa MP, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN 2014;12:1083-93.
  174. Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2015;191:7-16.
  175. Papavasiliou P, Hoffman JP, Cohen SJ, Meyer JE, Watson JC, Chun YS. Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. HPB : the official journal of the International Hepato Pancreato Biliary Association 2014;16:34-9.
  176. VanHouten JP, White RR, Jackson GP. A decision model of therapy for potentially resectable pancreatic cancer. The Journal of surgical research 2012;174:222-30.
  177. Sharma G, Whang EE, Ruan DT, Ito H. Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma: A Decision Analysis. Annals of surgical oncology 2015.
  178. Abbott DE, Tzeng CW, Merkow RP, et al. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Annals of surgical oncology 2013;20 Suppl 3:S500-8.
  179. Evans DB, Ritch PS, Erickson BA. Neoadjuvant therapy for localized pancreatic cancer: support is growing? Annals of surgery 2015;261:18-20.
  180. Adams MA, Anderson MA, Myles JD, Khalatbari S, Scheiman JM. Self-expanding metal stents (SEMS) provide superior outcomes compared to plastic stents for pancreatic cancer patients undergoing neoadjuvant therapy. Journal of gastrointestinal oncology 2012;3:309-13.
  181. Heinrich S, Schafer M, Weber A, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Annals of surgery 2008;248:1014-22.
  182. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA : the journal of the American Medical Association 2008;299:1019-26.
  183. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA : the journal of the American Medical Association 2007;297:267-77.
  184. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer 2007;110:1227-34.
  185. Raigani S, Ammori J, Kim J, Hardacre JM. Trends in the treatment of resectable pancreatic adenocarcinoma. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2014;18:113-23.
  186. Barbas AS, Turley RS, Ceppa EP, et al. Comparison of outcomes and the use of multimodality therapy in young and elderly people undergoing surgical resection of pancreatic cancer. Journal of the American Geriatrics Society 2012;60:344-50.
  187. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Archives of surgery (Chicago, Ill : 1960) 1985;120:899-903.
  188. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Annals of surgery 1999;230:776-82; discussion 82-4.
  189. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-85.
  190. Kimple RJ, Russo S, Monjazeb A, Blackstock AW. The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert review of anticancer therapy 2012;12:46980.
  191. Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26:3511-6.
  192. Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26:3503-10.
  193. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15:928-37.
  194. Valle JW, Palmer D, Jackson R, et al. Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014;32:504-12.
  195. Abrams RA, Lowy AM, O’Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Annals of surgical oncology 2009;16:1751-6.
  196. Gillmore R, Laurence V, Raouf S, et al. Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience. Clinical oncology (Royal College of Radiologists (Great Britain)) 2010;22:564-9.
  197. Christians KK, Tsai S, Mahmoud A, et al. Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm? The oncologist 2014.
  198. Rose JB, Rocha FG, Alseidi A, et al. Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival. Annals of surgical oncology 2014.
  199. Kadera BE, Sunjaya DB, Isacoff WH, et al. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival. JAMA surgery 2014;149:145-53.
  200. Petrelli F, Coinu A, Borgonovo K, et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas 2015;44:515-21.
  201. Lee JJ, Huang J, England CG, McNally LR, Frieboes HB. Predictive modeling of in vivo response to gemcitabine in pancreatic cancer. PLoS computational biology 2013;9:e1003231.
  202. Valentini V, Morganti AG, Macchia G, et al. Intraoperative radiation therapy in resected pancreatic carcinoma: long-term analysis. International journal of radiation oncology, biology, physics 2008;70:1094-9.
  203. Morganti AG, Picardi V, Ippolito E, et al. Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study. Acta oncologica (Stockholm, Sweden) 2010;49:418-22.
  204. Berber B, Sanabria JR, Braun K, et al. Emerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer. Expert review of anticancer therapy 2013;13:481-7.
  205. Combs SE, Habermehl D, Kessel K, et al. Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comparison with a 3D-treated patient cohort. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2013;189:738-44.
  206. Milano MT, Chmura SJ, Garofalo MC, et al. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. International journal of radiation oncology, biology, physics 2004;59:445-53.
  207. Abelson JA, Murphy JD, Minn AY, et al. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. International journal of radiation oncology, biology, physics 2012;82:e595-601.
  208. Ben-Josef E, Schipper M, Francis IR, et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. International journal of radiation oncology, biology, physics 2012;84:1166-71.
  209. Murphy JD, Chang DT, Abelson J, et al. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer 2012;118:1119-29.
  210. Goyal K, Einstein D, Ibarra RA, et al. Stereotactic body radiation therapy for nonresectable tumors of the pancreas. The Journal of surgical research 2012;174:319-25.
  211. Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009;115:665-72.
  212. Chuong MD, Springett GM, Freilich JM, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. International journal of radiation oncology, biology, physics 2013;86:516-22.
  213. Rwigema JC, Heron DE, Parikh SD, et al. Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins. Journal of gastrointestinal cancer 2012;43:70-6.
  214. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19:1592-9.
  215. Nichols RC, Jr. Huh SN, Prado KL, et al. Protons offer reduced normal-tissue exposure for patients receiving postoperative radiotherapy for resected pancreatic head cancer. International journal of radiation oncology, biology, physics 2012;83:158-63.
  216. Hong TS, Ryan DP, Blaszkowsky LS, et al. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. International journal of radiation oncology, biology, physics 2011;79:1517.
  217. Wo JY, Mamon HJ, Ferrone CR, et al. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2013.
  218. Saif MW. Advancements in the management of pancreatic cancer: 2013. JOP : Journal of the pancreas 2013;14:112-8.
  219. Guo XZ, Cui ZM, Liu X. Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer. World journal of gastrointestinal oncology 2013;5:20-8.
  220. Spano JP, Chodkiewicz C, Maurel J, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008;371:2101-8.
  221. Ma WW, Herman JM, Jimeno A, et al. A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Translational oncology 2010;3:373-9.
  222. Brett BT, Caplin ME. Towards immunotherapy for pancreatic cancer. Gut 2000;46:582-3.
  223. Abou-Alfa GK, Chapman PB, Feilchenfeldt J, et al. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. American journal of clinical oncology 2011;34:321-5.
  224. Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer immunology, immunotherapy : CII 2005;54:254-64.
  225. Bernhardt SL, Gjertsen MK, Trachsel S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. British journal of cancer 2006;95:1474-82.
  226. Koido S, Homma S, Takahara A, et al. Current immunotherapeutic approaches in pancreatic cancer. Clinical & developmental immunology 2011;2011:267539.
  227. Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Annals of surgery 2011;253:328-35.
  228. Gilliam AD, Broome P, Topuzov EG, et al. An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer. Pancreas 2012;41:374-9.
  229. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (New York, NY) 2011;331:1612-6.
  230. La Torre M, Ziparo V, Nigri G, Cavallini M, Balducci G, Ramacciato G. Malnutrition and pancreatic surgery: prevalence and outcomes. Journal of surgical oncology 2013;107:702-8.
  231. Afaneh C, Gerszberg D, Slattery E, Seres DS, Chabot JA, Kluger MD. Pancreatic cancer surgery and nutrition management: a review of the current literature. Hepatobiliary surgery and nutrition 2015;4:59-71.
  232. Eshuis WJ, van der Gaag NA, Rauws EA, et al. Therapeutic delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary drainage. Annals of surgery 2010;252:840-9.
  233. van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas. The New England journal of medicine 2010;362:129-37.
  234. Fang Y, Gurusamy KS, Wang Q, et al. Pre-operative biliary drainage for obstructive jaundice. The Cochrane database of systematic reviews 2012;9:Cd005444.
  235. Sauvanet A, Boher JM, Paye F, et al. Severe Jaundice Increases Early Severe Morbidity and Decreases Long-Term Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. Journal of the American College of Surgeons 2015;221:380-9.
  236. Christians KK, Tsai S, Tolat PP, Evans DB. Critical steps for pancreaticoduodenectomy in the setting of pancreatic adenocarcinoma. Journal of surgical oncology 2013;107:33-8.
  237. Myatra S, Divatia JV, Jibhkate B, Barreto GS, Shrikhande SV. Preoperative assessment and optimization in periampullary and pancreatic cancer. Indian journal of cancer 2011;48:86-93.
  238. Hodul P, Tansey J, Golts E, Oh D, Pickleman J, Aranha GV. Age is not a contraindication to pancreaticoduodenectomy. The American surgeon 2001;67:270-5; discussion 5-6.
  239. Hatzaras I, Schmidt C, Klemanski D, et al. Pancreatic resection in the octogenarian: a safe option for pancreatic malignancy. Journal of the American College of Surgeons 2011;212:373-7.
  240. Riall TS, Sheffield KM, Kuo YF, Townsend CM, Jr. Goodwin JS. Resection benefits older adults with locoregional pancreatic cancer despite greater short-term morbidity and mortality. Journal of the American Geriatrics Society 2011;59:647-54.
  241. Melis M, Marcon F, Masi A, et al. The safety of a pancreaticoduodenectomy in patients older than 80 years: risk vs. benefits. HPB : the official journal of the International Hepato Pancreato Biliary Association 2012;14:583-8.
  242. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American journal of clinical oncology 1982;5:649-55.
  243. Hill JS, Zhou Z, Simons JP, et al. A simple risk score to predict in-hospital mortality after pancreatic resection for cancer. Annals of surgical oncology 2010;17:1802-7.
  244. Greenblatt DY, Kelly KJ, Rajamanickam V, et al. Preoperative Factors Predict Perioperative Morbidity and Mortality After Pancreaticoduodenectomy. Annals of surgical oncology 2011;18:2126-35.
  245. Kelly KJ, Greenblatt DY, Wan Y, et al. Risk stratification for distal pancreatectomy utilizing ACSNSQIP: preoperative factors predict morbidity and mortality. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2011;15:250-9, discussion 9-61.
  246. Pratt W, Joseph S, Callery MP, Vollmer CM, Jr. POSSUM accurately predicts morbidity for pancreatic resection. Surgery 2008;143:8-19.
  247. Gawande AA, Kwaan MR, Regenbogen SE, Lipsitz SA, Zinner MJ. An Apgar score for surgery. Journal of the American College of Surgeons 2007;204:201-8.
  248. Whipple AO, Parsons WB, Mullins CR. TREATMENT OF CARCINOMA OF THE AMPULLA OF VATER. Annals of surgery 1935;102:763-79.
  249. DK NAaL. Neoplasms of the Exocrine Pancreas. In: Michael Mulholland KL, Gerard Doherty, Ronald Maier, Diane Simeone, Gilbert Upchurch, ed. Greenfield’s Surgery: Scientific Principles and Practice. 5th ed. Philadelphia: Lippincott Williams & Watkins.
  250. Murr MM, Sarr MG, Oishi AJ, van Heerden JA. Pancreatic cancer. CA: a cancer journal for clinicians 1994;44:304-18.
  251. Adsay NV, Basturk O, Saka B, et al. Whipple Made Simple For Surgical Pathologists: Orientation, Dissection, and Sampling of Pancreaticoduodenectomy Specimens For a More Practical and Accurate Evaluation of Pancreatic, Distal Common Bile Duct, and Ampullary Tumors. The American journal of surgical pathology 2014.
  252. Pitt HA, Grace PA. Cancer of the pancreas. Pylorus-preserving resection of the pancreas. Bailliere’s clinical gastroenterology 1990;4:917-30.
  253. Diener MK, Fitzmaurice C, Schwarzer G, et al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. The Cochrane database of systematic reviews 2014;11:Cd006053.
  254. Klinkenbijl JH, van der Schelling GP, Hop WC, van Pel R, Bruining HA, Jeekel J. The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region. Annals of surgery 1992;216:142-5.
  255. Kawai M, Tani M, Hirono S, et al. Pylorus ring resection reduces delayed gastric emptying in patients undergoing pancreatoduodenectomy: a prospective, randomized, controlled trial of pylorusresecting versus pylorus-preserving pancreatoduodenectomy. Annals of surgery 2011;253:495-501.
  256. Tani M, Terasawa H, Kawai M, et al. Improvement of delayed gastric emptying in pyloruspreserving pancreaticoduodenectomy: results of a prospective, randomized, controlled trial. Annals of surgery 2006;243:316-20.
  257. Gaedcke J, Gunawan B, Grade M, et al. The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbeck’s archives of surgery / Deutsche Gesellschaft fur Chirurgie 2010;395:451-8.
  258. Baque P, Iannelli A, Delotte J, de Peretti F, Bourgeon A. Division of the right posterior attachments of the head of the pancreas with a linear stapler during pancreaticoduodenectomy: vascular and oncological considerations based on an anatomical cadaver-based study. Surgical and radiologic anatomy : SRA 2009;31:13-7.
  259. Hackert T, Werner J, Weitz J, Schmidt J, Buchler MW. Uncinate process first—a novel approach for pancreatic head resection. Langenbeck’s archives of surgery / Deutsche Gesellschaft fur Chirurgie 2010;395:1161-4.
  260. Pessaux P, Rosso E, Panaro F, et al. Preliminary experience with the hanging maneuver for pancreaticoduodenectomy. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2009;35:1006-10.
  261. Artinyan A, Soriano PA, Prendergast C, Low T, Ellenhorn JD, Kim J. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB : the official journal of the International Hepato Pancreato Biliary Association 2008;10:371-6.
  262. van Heerden JA, McIlrath DC, Ilstrup DM, Weiland LH. Total pancreatectomy for ductal adenocarcinoma of the pancreas: an update. World journal of surgery 1988;12:658-62.
  263. Schmidt CM, Glant J, Winter JM, et al. Total pancreatectomy (R0 resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma. Surgery 2007;142:572-8; discussion 8-80.
  264. Reddy S, Wolfgang CL, Cameron JL, et al. Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival. Annals of surgery 2009;250:282-7.
  265. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Annals of surgery 2002;236:355-66; discussion 66-8.
  266. Riall TS, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma—part 3: update on 5-year survival. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2005;9:1191-204; discussion 204-6.
  267. Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Archives of surgery (Chicago, Ill : 1960) 2007;142:767-23; discussion 73-4.
  268. Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Annals of surgical oncology 2008;15:165-74.
  269. Tol JA, Gouma DJ, Bassi C, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 2014;156:591-600.
  270. Michalski CW, Kleeff J, Wente MN, Diener MK, Buchler MW, Friess H. Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. The British journal of surgery 2007;94:265-73.
  271. Jang JY, Kang MJ, Heo JS, et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Annals of surgery 2014;259:656-64.
  272. Henne-Bruns D, Vogel I, Luttges J, Kloppel G, Kremer B. Surgery for ductal adenocarcinoma of the pancreatic head: staging, complications, and survival after regional versus extended lymphadenectomy. World journal of surgery 2000;24:595-601; discussion -2.
  273. Park HJ, You DD, Choi DW, Heo JS, Choi SH. Role of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas. World journal of surgery 2014;38:186-93.
  274. Bassi C, Falconi M, Molinari E, et al. Duct-to-mucosa versus end-to-side pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: results of a prospective randomized trial. Surgery 2003;134:766-71.
  275. Berger AC, Howard TJ, Kennedy EP, et al. Does type of pancreaticojejunostomy after pancreaticoduodenectomy decrease rate of pancreatic fistula? A randomized, prospective, dualinstitution trial. Journal of the American College of Surgeons 2009;208:738-47; discussion 47-9.
  276. Que W, Fang H, Yan B, et al. Pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. American journal of surgery 2015;209:1074-82.
  277. Xiong JJ, Altaf K, Mukherjee R, et al. Systematic review and meta-analysis of outcomes after intraoperative pancreatic duct stent placement during pancreaticoduodenectomy. The British journal of surgery 2012;99:1050-61.
  278. Motoi F, Egawa S, Rikiyama T, Katayose Y, Unno M. Randomized clinical trial of external stent drainage of the pancreatic duct to reduce postoperative pancreatic fistula after pancreaticojejunostomy. The British journal of surgery 2012;99:524-31.
  279. Diener MK, Seiler CM, Rossion I, et al. Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet 2011;377:1514-22.
  280. Carter TI, Fong ZV, Hyslop T, et al. A dual-institution randomized controlled trial of remnant closure after distal pancreatectomy: does the addition of a falciform patch and fibrin glue improve outcomes? Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2013;17:102-9.
  281. Frozanpor F, Lundell L, Segersvard R, Arnelo U. The effect of prophylactic transpapillary pancreatic stent insertion on clinically significant leak rate following distal pancreatectomy: results of a prospective controlled clinical trial. Annals of surgery 2012;255:1032-6.
  282. Keck T, Kusters S, Wellner UF, Hopt UT, Karcz KW. Total laparoscopic partial pancreatoduodenectomy and reconstruction via laparoscopic pancreatogastrostomy. Langenbeck’s archives of surgery / Deutsche Gesellschaft fur Chirurgie 2012;397:1009-12.
  283. Gagner M, Pomp A. Laparoscopic pylorus-preserving pancreatoduodenectomy. Surgical endoscopy 1994;8:408-10.
  284. Baker EH, Ross SW, Seshadri R, et al. Robotic pancreaticoduodenectomy for pancreatic adenocarcinoma: role in 2014 and beyond. Journal of gastrointestinal oncology 2015;6:396-405.
  285. Venkat R, Edil BH, Schulick RD, Lidor AO, Makary MA, Wolfgang CL. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Annals of surgery 2012;255:1048-59.
  286. Kooby DA, Hawkins WG, Schmidt CM, et al. A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? Journal of the American College of Surgeons 2010;210:779-85, 86-7.
  287. Adam MA, Choudhury K, Goffredo P, et al. Minimally Invasive Distal Pancreatectomy for Cancer: Short-Term Oncologic Outcomes in 1733 Patients. World journal of surgery 2015;39:2564-72.
  288. Kooby DA, Gillespie T, Bentrem D, et al. Left-sided pancreatectomy: a multicenter comparison of laparoscopic and open approaches. Annals of surgery 2008;248:438-46.
  289. Magge D, Gooding W, Choudry H, et al. Comparative effectiveness of minimally invasive and open distal pancreatectomy for ductal adenocarcinoma. JAMA surgery 2013;148:525-31.
  290. Braga M, Ridolfi C, Balzano G, Castoldi R, Pecorelli N, Di Carlo V. Learning curve for laparoscopic distal pancreatectomy in a high-volume hospital. Updates in surgery 2012;64:179-83.
  291. Zhou NX, Chen JZ, Liu Q, et al. Outcomes of pancreatoduodenectomy with robotic surgery versus open surgery. The international journal of medical robotics + computer assisted surgery : MRCAS 2011;7:131-7.
  292. Abdelgadir Adam M, Choudhury K, Dinan MA, et al. Minimally Invasive Versus Open Pancreaticoduodenectomy for Cancer: Practice Patterns and Short-term Outcomes Among 7061 Patients. Annals of surgery 2015;262:372-7.
  293. Sharpe SM, Talamonti MS, Wang CE, et al. Early National Experience with Laparoscopic Pancreaticoduodenectomy for Ductal Adenocarcinoma: A Comparison of Laparoscopic Pancreaticoduodenectomy and Open Pancreaticoduodenectomy from the National Cancer Data Base. Journal of the American College of Surgeons 2015;221:175-84.
  294. Boone BA, Zenati M, Hogg ME, et al. Assessment of quality outcomes for robotic pancreaticoduodenectomy: identification of the learning curve. JAMA surgery 2015;150:416-22.
  295. Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2014;155:977-88.
  296. Evans DB, Farnell MB, Lillemoe KD, Vollmer C, Jr. Strasberg SM, Schulick RD. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Annals of surgical oncology 2009;16:1736-44.
  297. Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL. En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2002;6:147-57; discussion 57-8.
  298. Weitz J, Kienle P, Schmidt J, Friess H, Buchler MW. Portal vein resection for advanced pancreatic head cancer. Journal of the American College of Surgeons 2007;204:712-6.
  299. Shoup M, Conlon KC, Klimstra D, Brennan MF. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2003;7:946-52; discussion 52.
  300. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Annals of surgery 1997;226:248-57; discussion 5760.
  301. Chu CK, Farnell MB, Nguyen JH, et al. Prosthetic graft reconstruction after portal vein resection in pancreaticoduodenectomy: a multicenter analysis. Journal of the American College of Surgeons 2010;211:316-24.
  302. Yamamoto Y, Sakamoto Y, Nara S, et al. Reconstruction of the portal and hepatic veins using venous grafts customized from the bilateral gonadal veins. Langenbeck’s archives of surgery / Deutsche Gesellschaft fur Chirurgie 2009;394:1115-21.
  303. Fleming JB, Barnett CC, Clagett GP. Superficial femoral vein as a conduit for portal vein reconstruction during pancreaticoduodenectomy. Archives of surgery (Chicago, Ill : 1960) 2005;140:698701.
  304. Suzuki T, Yoshidome H, Kimura F, et al. Renal function is well maintained after use of left renal vein graft for vascular reconstruction in hepatobiliary-pancreatic surgery. Journal of the American College of Surgeons 2006;202:87-92.
  305. Lee DY, Mitchell EL, Jones MA, et al. Techniques and results of portal vein/superior mesenteric vein reconstruction using femoral and saphenous vein during pancreaticoduodenectomy. Journal of vascular surgery 2010;51:662-6.
  306. Turley RS, Peterson K, Barbas AS, et al. Vascular surgery collaboration during pancreaticoduodenectomy with vascular reconstruction. Annals of vascular surgery 2012;26:685-92.
  307. Kim SM, Min SK, Park D, et al. Reconstruction of portal vein and superior mesenteric vein after extensive resection for pancreatic cancer. Journal of the Korean Surgical Society 2013;84:346-52.
  308. Bachellier P, Nakano H, Oussoultzoglou PD, et al. Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile? American journal of surgery 2001;182:120-9.
  309. Aktekin A, Kucuk M, Odabasi M, et al. The importance of invasion and resection of superior mesenteric and portal veins in adenocarcinoma of the pancreas. Hepato-gastroenterology 2013;60:1194-8.
  310. Chua TC, Saxena A. Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2010;14:1442-52.
  311. Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric veinportal vein resection for pancreatic cancer: a meta-analysis. World journal of surgery 2012;36:884-91.
  312. Mollberg N, Rahbari NN, Koch M, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Annals of surgery 2011;254:882-93.
  313. Fuhrman GM, Leach SD, Staley CA, et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Annals of surgery 1996;223:154-62.
  314. Hackert T, Buchler MW. Vascular resections in pancreatic cancer. Updates in surgery 2010;62:73-4.
  315. Smoot RL, Donohue JH. Modified Appleby procedure for resection of tumors of the pancreatic body and tail with celiac axis involvement. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2012;16:2167-9.
  316. Beane JD, House MG, Pitt SC, et al. Distal pancreatectomy with celiac axis resection: what are the added risks? HPB : the official journal of the International Hepato Pancreato Biliary Association 2015;17:777-84.
  317. Hirano S, Kondo S, Hara T, et al. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results. Annals of surgery 2007;246:46-51.
  318. Christians KK, Pilgrim CH, Tsai S, et al. Arterial resection at the time of pancreatectomy for cancer. Surgery 2014;155:919-26.
  319. Hartwig W, Hackert T, Hinz U, et al. Multivisceral resection for pancreatic malignancies: riskanalysis and long-term outcome. Annals of surgery 2009;250:81-7.
  320. Burdelski CM, Reeh M, Bogoevski D, et al. Multivisceral resections in pancreatic cancer: identification of risk factors. World journal of surgery 2011;35:2756-63.
  321. Worni M, Castleberry AW, Clary BM, et al. Concomitant vascular reconstruction during pancreatectomy for malignant disease: a propensity score-adjusted, population-based trend analysis involving 10,206 patients. JAMA surgery 2013;148:331-8.
  322. Ravikumar R, Sabin C, Abu Hilal M, et al. Portal vein resection in borderline resectable pancreatic cancer: a United kingdom multicenter study. Journal of the American College of Surgeons 2014;218:40111.
  323. Smoot RL, Christein JD, Farnell MB. Durability of portal venous reconstruction following resection during pancreaticoduodenectomy. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2006;10:1371-5.
  324. Kneuertz PJ, Pitt HA, Bilimoria KY, et al. Risk of morbidity and mortality following hepatopancreato-biliary surgery. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2012;16:1727-35.
  325. Glasgow RE, Jackson HH, Neumayer L, et al. Pancreatic resection in Veterans Affairs and selected university medical centers: results of the patient safety in surgery study. Journal of the American College of Surgeons 2007;204:1252-60.
  326. Parikh P, Shiloach M, Cohen ME, et al. Pancreatectomy risk calculator: an ACS-NSQIP resource. HPB : the official journal of the International Hepato Pancreato Biliary Association 2010;12:488-97.
  327. Xu M, Hines OJ. Long-term Survival After Pancreatic Cancer: Hope Has Arrived. JAMA surgery 2015;150:710-1.
  328. Ghaferi AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated with inpatient surgery. The New England journal of medicine 2009;361:1368-75.
  329. Mann CD, Palser T, Briggs CD, et al. A review of factors predicting perioperative death and early outcome in hepatopancreaticobiliary cancer surgery. HPB : the official journal of the International Hepato Pancreato Biliary Association 2010;12:380-8.
  330. Hartwig W, Werner J, Jager D, Debus J, Buchler MW. Improvement of surgical results for pancreatic cancer. The Lancet Oncology 2013;14:e476-85.
  331. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138:8-13.
  332. McMillan MT, Vollmer CM, Jr. Asbun HJ, et al. The Characterization and Prediction of ISGPF Grade C Fistulas Following Pancreatoduodenectomy. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2015.
  333. Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer CM, Jr. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. Journal of the American College of Surgeons 2013;216:1-14.
  334. Gans SL, van Westreenen HL, Kiewiet JJ, Rauws EA, Gouma DJ, Boermeester MA. Systematic review and meta-analysis of somatostatin analogues for the treatment of pancreatic fistula. The British journal of surgery 2012;99:754-60.
  335. De Martino RR, Goodney PP, Spangler EL, et al. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. Journal of vascular surgery 2012;55:1035-40.e4.
  336. Hyder O, Dodson RM, Nathan H, et al. Influence of patient, physician, and hospital factors on 30day readmission following pancreatoduodenectomy in the United States. JAMA surgery 2013;148:1095102.
  337. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA : the journal of the American Medical Association 1998;280:1747-51.
  338. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2000;4:567-79.
  339. Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for highrisk surgery. The New England journal of medicine 2011;364:2128-37.
  340. Gooiker GA, van Gijn W, Wouters MW, Post PN, van de Velde CJ, Tollenaar RA. Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. The British journal of surgery 2011;98:485-94.
  341. Bilimoria KY, Talamonti MS, Sener SF, et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. Journal of the American College of Surgeons 2008;207:510-9.
  342. Bilimoria KY, Talamonti MS, Wayne JD, et al. Effect of hospital type and volume on lymph node evaluation for gastric and pancreatic cancer. Archives of surgery (Chicago, Ill : 1960) 2008;143:671-8; discussion 8.
  343. Joseph B, Morton JM, Hernandez-Boussard T, Rubinfeld I, Faraj C, Velanovich V. Relationship between hospital volume, system clinical resources, and mortality in pancreatic resection. Journal of the American College of Surgeons 2009;208:520-7.
  344. Ghaferi AA, Birkmeyer JD, Dimick JB. Hospital volume and failure to rescue with high-risk surgery. Medical care 2011;49:1076-81.
  345. Merkow RP, Bentrem DJ, Chung JW, Paruch JL, Ko CY, Bilimoria KY. Differences in patients, surgical complexity, and outcomes after cancer surgery at National Cancer Institute-designated cancer centers compared to other hospitals. Medical care 2013;51:606-13.
  346. Lemmens VE, Bosscha K, van der Schelling G, Brenninkmeijer S, Coebergh JW, de Hingh IH. Improving outcome for patients with pancreatic cancer through centralization. The British journal of surgery 2011;98:1455-62.
  347. Benassai G, Mastrorilli M, Quarto G, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. Journal of surgical oncology 2000;73:212-8.
  348. Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. American journal of surgery 1991;161:120-4; discussion 4-5.
  349. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. American journal of surgery 1993;165:68-72; discussion -3.
  350. Zhang JF, Hua R, Sun YW, et al. Influence of perineural invasion on survival and recurrence in patients with resected pancreatic cancer. Asian Pacific journal of cancer prevention : APJCP 2013;14:5133-9.
  351. Epstein AS, Soff GA, Capanu M, et al. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer 2012;118:3053-61.
  352. Butturini G, Stocken DD, Wente MN, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Archives of surgery (Chicago, Ill : 1960) 2008;143:75-83; discussion
  353. Mayo SC, Nathan H, Cameron JL, et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 2012;118:2674-81.
  354. Konstantinidis IT, Warshaw AL, Allen JN, et al. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a «true» R0 resection? Annals of surgery 2013;257:731-6.
  355. Paniccia A, Hosokawa P, Henderson W, et al. Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma. JAMA surgery 2015;150:701-10.
  356. Strobel O, Hartwig W, Hackert T, et al. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Annals of surgical oncology 2013;20:964-72.
  357. Asuthkar S, Rao JS, Gondi CS. Drugs in preclinical and early-stage clinical development for pancreatic cancer. Expert opinion on investigational drugs 2012;21:143-52.
  358. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and longterm outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013;310:1473-81.
  359. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2006;10:511-8.
  360. Gnerlich JL, Luka SR, Deshpande AD, et al. Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Archives of surgery (Chicago, Ill : 1960) 2012;147:753-60.
  361. Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2009;35:600-4.
  362. Castellanos JA, Merchant NB. Intensity of Follow-up after Pancreatic Cancer Resection. Annals of surgical oncology 2014;21:747-51.
  363. Sheffield KM, Crowell KT, Lin YL, Djukom C, Goodwin JS, Riall TS. Surveillance of pancreatic cancer patients after surgical resection. Annals of surgical oncology 2012;19:1670-7.
  364. La Torre M, Nigri G, Lo Conte A, et al. Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection? Gut and liver 2014;8:102-8.
  365. Kinsella TJ, Seo Y, Willis J, et al. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FUbased concurrent chemotherapy for resectable pancreatic cancer. American journal of clinical oncology 2008;31:446-53.
  366. Katz MH, Wang H, Balachandran A, et al. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2012;16:68-78; discussion -9.
  367. Bogoevski D, Yekebas EF, Schurr P, et al. Mode of spread in the early phase of lymphatic metastasis in pancreatic ductal adenocarcinoma: prognostic significance of nodal microinvolvement. Annals of surgery 2004;240:993-1000; discussion -1.
  368. Hamidian Jahromi A, Sangster G, Zibari G, et al. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma. JOP : Journal of the pancreas 2013;14:466-8.
  369. Habermehl D, Brecht IC, Bergmann F, et al. Chemoradiation in patients with isolated recurrent pancreatic cancer therapeutical efficacy and probability of re-resection. Radiation oncology (London, England) 2013;8:27.
  370. Nakamura A, Itasaka S, Takaori K, et al. Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer : Prolonged disease-free interval associated with favorable prognosis. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2014.
  371. Kleeff J, Reiser C, Hinz U, et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Annals of surgery 2007;245:566-72.
  372. Roeder F, Timke C, Uhl M, et al. Aggressive local treatment containing intraoperative radiation therapy (IORT) for patients with isolated local recurrences of pancreatic cancer: a retrospective analysis. BMC cancer 2012;12:295.
  373. Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13:748-55.
  374. House MG, Choti MA. Palliative therapy for pancreatic/biliary cancer. The Surgical clinics of North America 2005;85:359-71.

 

  1. Staats PS, Hekmat H, Sauter P, Lillemoe K. The effects of alcohol celiac plexus block, pain, and mood on longevity in patients with unresectable pancreatic cancer: a double-blind, randomized, placebo-controlled study. Pain medicine (Malden, Mass) 2001;2:28-34.
  2. Rykowski JJ, Hilgier M. Efficacy of neurolytic celiac plexus block in varying locations of pancreatic cancer: influence on pain relief. Anesthesiology 2000;92:347-54.
  3. Shaikh TR, Desai P. Multimodal analgesia is central to alleviating pain in pancreatic adenocarcinoma. BMJ (Clinical research ed) 2012;345:e4307.
  4. Bukki J. Pancreatic adenocarcinoma. The New England journal of medicine 2014;371:2139-40.
  5. Turaga KK, Malafa MP, Jacobsen PB, Schell MJ, Sarr MG. Suicide in patients with pancreatic cancer. Cancer 2011;117:642-7.
  6. Petzel MQ, Parker NH, Valentine AD, et al. Fear of cancer recurrence after curative pancreatectomy: a cross-sectional study in survivors of pancreatic and periampullary tumors. Annals of surgical oncology 2012;19:4078-84.
  7. Chan C, Franssen B, Dominguez I, Ramirez-Del Val A, Uscanga LF, Campuzano M. Impact on quality of life after pancreatoduodenectomy: a prospective study comparing preoperative and postoperative scores. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2012;16:1341-6.
  8. Gerstenhaber F, Grossman J, Lubezky N, et al. Pancreaticoduodenectomy in elderly adults: is it justified in terms of mortality, long-term morbidity, and quality of life? Journal of the American Geriatrics Society 2013;61:1351-7.
  9. Schniewind B, Bestmann B, Henne-Bruns D, Faendrich F, Kremer B, Kuechler T. Quality of life after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head. The British journal of surgery 2006;93:1099-107.
  10. Morak MJ, Pek CJ, Kompanje EJ, Hop WC, Kazemier G, van Eijck CH. Quality of life after adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled study. Cancer 2010;116:830-6.
  11. Sultana A, Tudur Smith C, Cunningham D, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. British journal of cancer 2007;96:1183-90.
  12. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15:2403-13.
  13. De La Cruz MS, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. American family physician 2014;89:626-32.
  14. Moyer MT, Gaffney RR. Pancreatic adenocarcinoma. The New England journal of medicine 2014;371:2140.
  15. Sheffield KM, Boyd CA, Benarroch-Gampel J, Kuo YF, Cooksley CD, Riall TS. End-of-life care in Medicare beneficiaries dying with pancreatic cancer. Cancer 2011;117:5003-12.
  16. Gomez-Martin C, Hidalgo M, Tabernero J, Isla D. SEOM clinical guidelines for the treatment of pancreatic cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2011;13:528-35.
  17. Di Fronzo LA, Cymerman J, Egrari S, O’Connell TX. Unresectable pancreatic carcinoma: correlating length of survival with choice of palliative bypass. The American surgeon 1999;65:955-8.
  18. Sarfeh IJ, Rypins EB, Jakowatz JG, Juler GL. A prospective, randomized clinical investigation of cholecystoenterostomy and choledochoenterostomy. American journal of surgery 1988;155:411-4.
  19. Huser N, Michalski CW, Schuster T, Friess H, Kleeff J. Systematic review and meta-analysis of prophylactic gastroenterostomy for unresectable advanced pancreatic cancer. The British journal of surgery 2009;96:711-9.
  20. Shah A, Fehmi A, Savides TJ. Increased rates of duodenal obstruction in pancreatic cancer patients receiving modern medical management. Digestive diseases and sciences 2014;59:2294-8.
  21. Gillen S, Schuster T, Friess H, Kleeff J. Palliative resections versus palliative bypass procedures in pancreatic cancer-a systematic review. American journal of surgery 2012;203:496-502.
  22. Puli SR, Reddy JB, Bechtold ML, Antillon MR, Brugge WR. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain: a meta-analysis and systematic review. Digestive diseases and sciences 2009;54:2330-7.
  23. Polati E, Finco G, Gottin L, Bassi C, Pederzoli P, Ischia S. Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer. The British journal of surgery 1998;85:199-201.
  24. Allen PJ, Chou J, Janakos M, Strong VE, Coit DG, Brennan MF. Prospective evaluation of laparoscopic celiac plexus block in patients with unresectable pancreatic adenocarcinoma. Annals of surgical oncology 2011;18:636-41.
  25. Pietrabissa A, Vistoli F, Carobbi A, Boggi U, Bisa M, Mosca F. Thoracoscopic splanchnicectomy for pain relief in unresectable pancreatic cancer. Archives of surgery (Chicago, Ill : 1960) 2000;135:332-5.
  26. Smigielski J, Piskorz L, Wawrzycki M, Kutwin L, Misiak P, Brocki M. Assessment of quality of life in patients with non-operated pancreatic cancer after videothoracoscopic splanchnicectomy. Wideochirurgia i inne techniki malo inwazyjne = Videosurgery and other miniinvasive techniques / kwartalnik pod patronatem Sekcji Wideochirurgii TChP oraz Sekcji Chirurgii Bariatrycznej TChP 2011;6:132-7.
  27. Beger HG BD. Pancreatic cancer staging systems and their clinical impact. 2nd Ed. In: Beger H WA, Bьchler M, ed. The pancreas: an integrated textbook of basic science, medicine, and surgery. Oxford, England: Blackwell; 2008.
  28. Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. The Cochrane database of systematic reviews 2006:Cd004200.
  29. Shepherd HA, Royle G, Ross AP, Diba A, Arthur M, Colin-Jones D. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial. The British journal of surgery 1988;75:1166-8.
  30. Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994;344:1655-60.
  31. Taylor MC, McLeod RS, Langer B. Biliary stenting versus bypass surgery for the palliation of malignant distal bile duct obstruction: a meta-analysis. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2000;6:302-8.
  32. Glazer ES, Hornbrook MC, Krouse RS. A Meta-Analysis of Randomized Trials: Immediate Stent Placement vs. Surgical Bypass in the Palliative Management of Malignant Biliary Obstruction. Journal of pain and symptom management 2014;47:307-14.
  33. Lillemoe KD, Pitt HA. Palliation. Surgical and otherwise. Cancer 1996;78:605-14.
  34. van der Schelling GP, van den Bosch RP, Klinkenbij JH, Mulder PG, Jeekel J. Is there a place for gastroenterostomy in patients with advanced cancer of the head of the pancreas? World journal of surgery 1993;17:128-32; discussion 32-3.
  35. Bartlett EK, Wachtel H, Fraker DL, et al. Surgical palliation for pancreatic malignancy: practice patterns and predictors of morbidity and mortality. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2014;18:1292-8.
  36. Assfalg V, Huser N, Michalski C, Gillen S, Kleeff J, Friess H. Palliative interventional and surgical therapy for unresectable pancreatic cancer. Cancers 2011;3:652-61.
  37. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7:593-600.
  38. Von Hoff DD, Goldstein D, Renschler MF. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. The New England journal of medicine 2014;370:479-80.
  39. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27:5513-8.
  40. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med 2011;364:1817-25.
  41. Bayraktar S, Bayraktar UD, Rocha-Lima CM. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World journal of gastroenterology : WJG 2010;16:67382.
  42. Johung K, Saif MW, Chang BW. Treatment of locally advanced pancreatic cancer: the role of radiation therapy. International journal of radiation oncology, biology, physics 2012;82:508-18.
  43. Cardenes HR, Moore AM, Johnson CS, et al. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study. American journal of clinical oncology 2011;34:460-5.
  44. Cai S, Hong TS, Goldberg SI, et al. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer 2013;119:4196-204.
  45. Mahadevan A, Jain S, Goldstein M, et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics 2010;78:735-42.
  46. Sanders MK, Moser AJ, Khalid A, et al. EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer. Gastrointestinal endoscopy 2010;71:1178-84.
  47. Su TS, Liang P, Lu HZ, et al. Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer. World journal of gastroenterology : WJG 2015;21:815662.
  48. Polistina F, Costantin G, Casamassima F, et al. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Annals of surgical oncology 2010;17:2092-101.
  49. Schellenberg D, Kim J, Christman-Skieller C, et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics 2011;81:181-8.
  50. Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 2015;121:1128-37.
  51. Pollom EL, Alagappan M, von Eyben R, et al. Singleversus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. International journal of radiation oncology, biology, physics 2014;90:918-25.
  52. Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2005;76:48-53.
  53. Gurka MK, Kim C, He AR, et al. Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. American journal of clinical oncology 2014.
  54. Kim CH, Ling DC, Wegner RE, et al. Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients. Radiation oncology (London, England) 2013;8:240.
  55. Engelhardt K, Riley C, Cooke L, Mahadevan D. Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma. Current drug discovery technologies 2006;3:231-43.
  56. Heinemann V, Ebert MP, Laubender RP, Bevan P, Mala C, Boeck S. Phase II randomised proof-ofconcept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. British journal of cancer 2013;108:766-70.
  57. Rombouts SJ, Vogel JA, van Santvoort HC, et al. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. The British journal of surgery 2015;102:182-93.
  58. Cao C, Yan TD, Morris DL, Bester L. Radioembolization with yttrium-90 microspheres for pancreatic cancer liver metastases: results from a pilot study. Tumori 2010;96:955-8.
  59. Carrafiello G, Ierardi AM, Fontana F, et al. Microwave ablation of pancreatic head cancer: safety and efficacy. Journal of vascular and interventional radiology : JVIR 2013;24:1513-20.
  60. Lee JY, Choi BI, Ryu JK, et al. Concurrent chemotherapy and pulsed high-intensity focused ultrasound therapy for the treatment of unresectable pancreatic cancer: initial experiences. Korean journal of radiology : official journal of the Korean Radiological Society 2011;12:176-86.
  61. Combs SE, Habermehl D, Kieser M, et al. Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial. BMC cancer 2013;13:419.
  62. Huggett MT, Jermyn M, Gillams A, et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. British journal of cancer 2014.
  63. Ansari D, Chen BC, Dong L, Zhou MT, Andersson R. Pancreatic cancer: translational research aspects and clinical implications. World journal of gastroenterology : WJG 2012;18:1417-24.
  64. Schultz NA, Dehlendorff C, Jensen BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA : the journal of the American Medical Association 2014;311:392-404.
  65. Bouvet M, Hoffman RM. In vivo imaging of pancreatic cancer with fluorescent proteins in mouse models. Methods in molecular biology (Clifton, NJ) 2012;872:51-67.
  66. Metildi CA, Kaushal S, Hardamon CR, et al. Fluorescence-guided surgery allows for more complete resection of pancreatic cancer, resulting in longer disease-free survival compared with standard surgery in orthotopic mouse models. Journal of the American College of Surgeons 2012;215:126-35; discussion 35-6.
  67. Abe Y, Itano O, Kitago M, et al. Computer assisted surgery, preoperative planning and navigation for pancreatic cancer. Journal of hepato-biliary-pancreatic sciences 2014.
  68. Zhan Q, Shen B, Deng X, et al. Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery. International journal of nanomedicine 2013;8:2465-72.
  69. Tseng JF, Mulligan RC. Gene therapy for pancreatic cancer. Surgical oncology clinics of North America 2002;11:537-69.
  70. Pawlik TM, Laheru D, Hruban RH, et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Annals of surgical oncology 2008;15:2081-8.
  71. Chang KJ, Parasher G, Christie C, Largent J, Anton-Culver H. Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups. Cancer 2005;103:349-57.
  72. Chang DC, Zhang Y, Mukherjee D, et al. Variations in referral patterns to high-volume centers for pancreatic cancer. Journal of the American College of Surgeons 2009;209:720-6.
  73. Cheung MC, Yang R, Byrne MM, Solorzano CC, Nakeeb A, Koniaris LG. Are patients of low socioeconomic status receiving suboptimal management for pancreatic adenocarcinoma? Cancer 2010;116:723-33.
  74. Helling TS. Pancreas cancer in Mississippi: present challenges and future directions. Journal of the Mississippi State Medical Association 2010;51:99-103.
  75. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Annals of surgery 2007;246:173-80.
  76. Talamonti MS, Small W, Jr. Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Annals of surgical oncology 2006;13:150-8.
  77. Heinrich S, Pestalozzi BC, Schafer M, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26:252631.
  78. Le Scodan R, Mornex F, Girard N, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol 2009;20:1387-96.
  79. Turrini O, Ychou M, Moureau-Zabotto L, et al. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2010;36:987-92.
  80. Pipas JM, Zaki BI, McGowan MM, et al. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. Ann Oncol 2012;23:2820-7.
  81. Takahashi H, Ohigashi H, Ishikawa O, et al. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabinebased chemoradiation therapy for resectable pancreatic cancer. Annals of surgery 2012;255:95-102.
  82. Van Buren G, 2nd, Ramanathan RK, Krasinskas AM, et al. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol 2013;20:3787-93.
  83. Kim EJ, Ben-Josef E, Herman JM, et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 2013;119:2692-700.
  84. Motoi F, Ishida K, Fujishima F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multiinstitutional phase 2 trial. Annals of surgical oncology 2013;20:3794-801.
  85. Hong TS, Ryan DP, Borger DR, et al. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. International journal of radiation oncology, biology, physics 2014;89:830-8.
  86. O’Reilly EM, Perelshteyn A, Jarnagin WR, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Annals of surgery 2014;260:142-8.
  87. Takeda Y, Nakamori S, Eguchi H, et al. Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma. Japanese journal of clinical oncology 2014;44:1172-80.
  88. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-85.
  89. Demols A, Peeters M, Polus M, et al. Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study. International journal of radiation oncology, biology, physics 2005;62:1351-6.
  90. Blackstock AW, Mornex F, Partensky C, et al. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. British journal of cancer 2006;95:260-5.
  91. Kosuge T, Kiuchi T, Mukai K, Kakizoe T. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Japanese journal of clinical oncology 2006;36:159-65.
  92. Yoshitomi H, Togawa A, Kimura F, et al. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer 2008;113:2448-56.
  93. Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009;101:908-15.
  94. Van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabinebased chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-4001322012/FFCD-9203/GERCOR phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28:4450-6.
  95. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA : the journal of the American Medical Association 2010;304:1073-81.
  96. Reni M, Balzano G, Aprile G, et al. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Annals of surgical oncology 2012;19:2256-63.
  97. Schmidt J, Abel U, Debus J, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30:4077-83.
  98. Fensterer H, Schade-Brittinger C, Muller HH, et al. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24:257681.
  99. Herman JM, Fan KY, Wild AT, et al. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. International journal of radiation oncology, biology, physics 2013;86:678-85.
0